why choose us

First received: June 06, 2023

Clinical Trial: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Uveal Melanoma

Study Type: INTERVENTIONAL


Official Title: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Brief Summary: Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Read more